Jul 17, 2020 / NTS GMT
James F. List - Janssen Global Services, LLC - Global Therapeutic Area Head of Cardiovascular & Metabolism(CVM)
Hi. I'm Jim List, Global Head of the Cardiovascular, Metabolism and Retinal team at Janssen. I have the privilege of sharing how we're improving the lives of millions of people impacted by eye diseases.
Today, I'll highlight new data from the Phase I/II clinical trial of the gene therapy we're developing with MeiraGTx to treat X-linked retinitis pigmentosa, a rare inherited retinal disease. I'll also touch on why we're focused in this space and our overall strategy.
But first, please take a moment to read our cautionary note on forward-looking statements contained in this webcast.
Janssen is the pharmaceutical arm of Johnson & Johnson, and we are proud to be part of the broadest and most diversified health care company. Johnson & Johnson has long-standing leadership in both consumer and surgical devices through J&J Vision. Janssen's entry into eye disease only extends our commitment to support patients living with diseases of the eye.
Johnson & Johnson to Review Interim Data from the Phase 1/2 RPGR Clinical Trial and Janssen's Retinal Portfolio Strategy (Pre-recorded) Transcript
Jul 17, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers